Free Trial
→ Rent out your stocks? (From Profits Run) (Ad)tc pixel
NASDAQ:IRD

Opus Genetics Q3 2026 Earnings Date & Estimates

Opus Genetics logo
$4.22 -0.02 (-0.35%)
As of 12:25 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Opus Genetics is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. The conference call is scheduled for November 12, 2026 at 12:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
12:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Opus Genetics in Q3 2026

Opus Genetics is expected to post earnings of -$0.14 per share on revenue of $1.54 million. In the same quarter a year earlier Opus Genetics reported -$0.12 per share on revenue of $3.08 million. Opus Genetics last reported on August 6, 2026, posting -$0.14 per share and beating the -$0.1567 consensus estimate. Opus Genetics has beaten the consensus EPS estimate in 5 of its last 7 quarters.

Consensus Estimates

Consensus EPS
-$0.14
Expected Revenue
$1.54 million
Prior-Year EPS
-$0.12
Prior-Year Revenue
$3.08 million
Expected Revenue Growth
-49.9%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.14 (Beat by +$0.0167)
Last Quarter Revenue
$0.76 million
EPS Beat Rate
5 of last 7 quarters

Prepare for the Q3 2026 Call

Opus Genetics Q3 2026 Earnings FAQ

Opus Genetics (NASDAQ:IRD) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Opus Genetics' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Opus Genetics to post earnings of -$0.14 per share for Q3 2026.

The consensus revenue estimate for Opus Genetics is $1.54 million for Q3 2026.

Opus Genetics Earnings Headlines

Opus Genetics to Present at the Chardan Annual Healthcare Conference
October 13 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/13/3379530/0/en/opus-genetics-to-present-at-the-chardan-annual-healthcare-conference.html
Could an FDA Nod for MR-141 Give Viatris (VTRS) and Opus Genetics (IRD) a Presbyopia Payoff?
October 8, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/news/could-an-fda-nod-for-mr-141-give-viatris-vtrs-and-opus-genetics-ird-a-presbyopia-payoff-1851198/
Wall Street legend reveals his top AI stock before Oct. 20
Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock ahead of October 20. His system has spotted at least seven of the top 10 performers every year since 2016, including all ten in the 2022 bear market and every member of the Magnificent Seven before their run higher. Now Chaikin's Power Gauge is turning bullish on an under-the-radar company tied to next-generation AI data centers built under Executive Order 14363, technology he says uses 99 percent less electricity and space while offering far greater computing power.tc pixel
October 14 at 1:00 AM  |  Chaikin Analytics (Ad)
Could an FDA Nod for MR-141 Give Viatris (VTRS) and Opus Genetics (IRD) a Presbyopia Payoff?
October 8, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/could-fda-nod-mr-141-225535714.html
JonesTrading Forecasts Strong Price Appreciation for Opus Genetics (NASDAQ:IRD) Stock
October 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31097846
Head to Head Survey: Atara Biotherapeutics (NASDAQ:ATRA) versus Opus Genetics (NASDAQ:IRD)
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31086125
See More Opus Genetics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Opus Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Opus Genetics and other key companies, straight to your email.

About Opus Genetics

Opus Genetics (NASDAQ:IRD) is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases, a group of rare disorders that can cause progressive vision loss and blindness. The company’s research is centered on therapies intended to address the underlying genetic causes of these conditions rather than treating only their symptoms.

Opus Genetics is advancing an investigational pipeline of adeno-associated virus-based gene therapy candidates for diseases involving mutations in genes important to retinal function. Its programs are designed to deliver functional genetic material or otherwise correct disease-related biological processes in retinal cells. The company’s lead programs target selected forms of inherited retinitis pigmentosa and other rare retinal disorders.

Founded in 2017, Opus Genetics is based in Durham, North Carolina, and conducts its development activities through collaborations with researchers, medical institutions, and clinical trial sites. As its therapies remain investigational, their safety and effectiveness have not been established for general use.

View Opus Genetics Profile
Earnings Tools